1. Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and S4) in tumor cells in vivo at 96 hours are summarized.
Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and S4) in tumor cells in vivo at 96 hours are summarized. A, the average fold changes in expression of the most significantly enriched genes for each gene set (leading edge genes) are shown: Left, motif-based gene sets, Right, curated gene sets. Asterisk indicates P-value of the comparison between the two groups of patients (Student's t-test). B, heatmap of fold change mRNA expression of proteasome subunits in response to bortezomib at 96 hours. Immunoblot of β5 subunit (PSMB5) protein expression in CD19-selected tumor cells. p97 was used as loading control. C, heatmap of the fold-change expression of experimentally validated NRF2 signature genes (36) ranked by the average fold change in MCL1 and MCL3 at 96 hours of bortezomib treatment in vivo. D, the averaged fold-change mRNA expression of the NRF2 signature genes is shown (P = 0.034, Student's t-test). Immunoblot of NRF2 protein expression in CD19-selected tumor cells before and 96 hours of bortezomib treatment in vivo. p97 was used as loading control.
Marc A. Weniger et al. Clin Cancer Res 2011;17:
©2011 by American Association for Cancer Research